UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations

被引：1
|
作者：
Miura, S. [1 ]
Hsia, T-C. [2 ]
Hung, J-Y. [3 ]
Jung, H. A. [4 ]
Shih, J-Y. [5 ,6 ]
Yang, T-Y. [7 ]
Park, C-K. [8 ]
Lee, S. H. [9 ]
Okamoto, T. [10 ]
Ahn, H. K. [11 ]
Lee, Y. C. [12 ]
Sato, Y. [13 ]
Lee, S. S. [14 ]
Mascaux, C. [15 ]
Daoud, H. [16 ]
Maerten, A. [16 ]
Popat, S. [17 ,18 ]
机构：
[1] Niigata Univ, Div Resp Med, Dept Homeostat Regulat & Dev, Niigata, Japan
[2] China Med Univ, China Med Univ Hosp, Dept Resp Therapy, Dept Internal Med, Taichung, Taiwan
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan
[4] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[5] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[6] Taichung Vet Gen Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan
[7] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei, Taiwan
[8] Chonnam Natl Univ, Dept Internal Med, Hwasun Hosp, Hwasun, South Korea
[9] Kyung Hee Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med,Med Ctr, Seoul, South Korea
[10] Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[11] Gachon Univ, Div Med Oncol, Gil Med Ctr, Incheon, South Korea
[12] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Dept Internal Med, Res Inst Clin Med,Biomed Res Inst,Med Sch, Jeonju, South Korea
[13] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan
[14] Inje Univ, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[15] Univ Strasbourg, Strasbourg Univ Hosp, Dept Pulm, Strasbourg, France
[16] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[17] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[18] Inst Canc Res, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(21)01987-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
145P
引用
收藏
页码：S776 / S777
页数：2
相关论文
共 50 条
  • [1] UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations.
    Miura, Satoru
    Hsia, Te-Chun
    Hung, Jen-Yu
    Jung, Hyun Ae
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Park, Cheol-Kyu
    Lee, Seung Hyeun
    Okamoto, Tatsuro
    Ahn, Hee Kyung
    Lee, Yong Chul
    Sato, Yuki
    Lee, Sung Sook
    Mascaux, Celine
    Daoud, Hasan
    Maerten, Angela
    Popat, Sanjay
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [2] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
    Miura, S.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
  • [3] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [4] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice
    Maerten, Angela
    Brueckl, Wolfgang
    Laack, Eckhart
    Hoffmann, Christopher
    Zhou, Caicun
    Wu, Yi-Long
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 160
  • [5] Afatinib in EGFR Mutation-Positive (EGFRm plus ) NSCLC Harbouring Uncommon Mutations: Experience in 'Real-World' Clinical Practice
    Brueckl, W.
    Laack, E.
    Hoffmann, C.
    Zhou, C.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S671
  • [6] Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations
    Yang, J. C-H.
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S860 - S861
  • [7] A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
    Miura, S.
    Hsia, T.
    Hung, J.
    Jung, H. A.
    Shih, J.
    Park, C.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1115 - S1116
  • [8] Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations
    Yang, J. Chih-Hsin
    Schuler, M.
    Popat, S.
    Miura, S.
    Heeke, S.
    Passaro, A.
    de Marinis, F.
    Park, K.
    Kim, E. S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S31
  • [9] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
    Popat, S.
    Jung, H. A.
    Lee, S. Yup
    Hochmair, M. J.
    Lee, S. H.
    Escriu, C.
    Lee, M. K.
    Migliorino, M. R.
    Lee, Y. C.
    Girard, N.
    Daoud, H.
    Maerten, A.
    Miura, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S971 - S972
  • [10] Afatinib in Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
    Arrieta, O.
    De Marchi, P.
    Yamamoto, N.
    Yu, C.
    Ou, S. I.
    Zhou, C.
    Paskevicius, M.
    Maerten, A.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S165 - S165
12345